Seroxat USERS collaborate with MHRA Expert Working Group

10.3 The Group was informed that the Seroxat Users Group, which is a UK patient support group, has been in correspondence with the MHRA and its predecessor the Medicines Control Agency expressing its concerns about the safety of paroxetine. The MHRA had informed the Seroxat Users Group of its willingness to consider any reports of suspected adverse drug reactions submitted by members of the Seroxat User Group. In recent correspondence the Seroxat Users Group has expressed an interest in meeting with the Expert Group in order to contribute to its work.


10.4 The Expert Group commented that the views of the Seroxat User Group would provide a valuable contribution to the ongoing review. It was agreed that the Seroxat

 
Users Group should be given the opportunity to make a presentation to the Group should they wish. However, they might prefer a less formal meeting between representatives of the Expert Group and members of the MHRA to discuss their concerns. It was agreed that it would be helpful if the Seroxat Users Group provided a written representation which could then be considered by the Group.
http://www.mhra.gov.uk/home/groups/pl-p/documents/committeedocument/con003485.pdf